"EMA's acceptance to review our applications on marketing Trastuzumab and Pegfilgrastim biosimilars is a welcome development, as they were resubmitted after taking corrective and preventive actions, including modifications of our drug making facility," said Biocon's Chief Executive Arun Chandavarkar in a statement here.
The pharma company hoped the regulator would verify its corrective actions during the inspection of its production facility soon as part of the review process.
"We will engage with the regulator to provide quality and affordable therapy options for cancer patients in Europe."
(This story has not been edited by Social News XYZ staff and is auto-generated from a syndicated feed.)
Doraiah Chowdary Vundavally is a Software engineer at VTech . He is the news editor of SocialNews.XYZ and Freelance writer-contributes Telugu and English Columns on Films, Politics, and Gossips. He is the primary contributor for South Cinema Section of SocialNews.XYZ. His mission is to help to develop SocialNews.XYZ into a News website that has no bias or judgement towards any.
This website uses cookies.